Publications by authors named "Kin-Chun Luk"

Claim this Profile
D
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
Zhuming Zhang, Qingjie Ding, Jin-Jun Liu, Jing Zhang, Nan Jiang, Kin-Chun Luk

Bioorg Med Chem· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Kevin Anderson, Yi Chen, Zhi Chen, Romyr Dominique, Kelli Glenn, Kin-Chun Luk, Christine Lukacs

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.
Fernando Padilla, Niala Bhagirath, Shaoqing Chen, Eric Chiao, David M Goldstein, Kin Chun Luk

J Med Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.
Jin-Jun Liu, Brian Higgins, Grace Ju, Kenneth Kolinsky, Kin-Chun Luk

ACS Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of highly selective spleen tyrosine kinase inhibitors.
Matthew C Lucas, David M Goldstein, Johannes C Hermann, Andreas Kuglstatter, Wenjian Liu, Kin Chun Luk

J Med Chem· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Shaoqing Chen, David Bartkovitz, Jianping Cai, Yi Chen, Zhi Chen, Kin-Chun Luk

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
Daina Z Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-Chun Luk

Mol Cancer Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.
Lee A McDermott, Brian Higgins, Mary Simcox, Kin-Chun Luk, Tom Nevins

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.
Lee A McDermott, Mary Simcox, Brian Higgins, Tom Nevins, Kenneth Kolinsky, Kin-Chun Luk

Bioorg Med Chem· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new series of potent oxindole inhibitors of CDK2.
Kin-Chun Luk, Mary Ellen Simcox, Andy Schutt, Karen Rowan, Thelma Thompson

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors.
Jin-Jun Liu, Apostolos Dermatakis, Christine Lukacs, Fred Konzelmann, Yi Chen, Kin-Chun Luk

Bioorg Med Chem Lett· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of potent oxindole CDK2 inhibitors.
Apos Dermatakis, Kin Chun Luk, Wanda DePinto

Bioorg Med Chem· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis